This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial | MicrobiomeTrials
← Back to trials NCT07426705
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-02-15Est. Completion: 2027-07-15
Enrollment target: 100 participantsOther microbiome trials you might be interested in Irritable Bowel Syndrome (IBS) Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal ba…
Baltimore, United States Est. completion Dec 31, 2027
Food Intolerance Syndromes Small Intestinal Bacterial Overgrowth Syndrome (SIBO) Breath Tests
Hydrogen (H₂) breath tests serve several purposes. (i) detect malabsorption of carbohydrates such as lactose and fructos…
Arlesheim, Switzerland Completed Dec 31, 2025
Eosinophilic Esophagitis Gastroesophageal Reflux Disease (GERD) Gastroparesis Functional Vomiting Irritable Bowel Syndrome (IBS) Constipation Chronic Intestinal Pseudo-obstruction Fecal Incontinence Small Intestinal Bacterial Overgrowth
Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to …
Indianapolis, United States Est. completion Nov 2026